Coronavirus Study to Look at Using Gout Drug to Prevent Lung Complications and Deaths from COVID-19By Kashmira Gander On 3/24/20 at 12:26 PM EDT
Scientists in Canada have launched a study to test a drug they hope could prevent people from dying of lung complications caused by the respiratory disease COVID-19.
Researchers at the Montreal Heart Institute aim to recruit 6,000 COVID-19 patients for their COLCORONA study, according to a statement. The drug, called colchicine, is an anti-inflammatory pill used to treat gout, Behcet's syndrome —which causes blood vessel inflammation— and the genetic disorder Familial Mediterranean Fever, where people have a recurrent abnormal body temperature.
Professor Jean-Claude Tardif, director of the Research Centre at the Montreal Heart Institute, told Radio Canada his team believes the medication could stop what is known as a cytokine storm, where the immune system overreacts.
Related Stories
The drug "may reduce COVID-19-related complications in adults at risk or with evidence of an inflammatory storm," according to the institute's statement. ...
Newsweek